66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

Key Takeaways Explain This Topic AI

Advance directives include the Durable Power of Attorney for Healthcare (designating a surrogate who applies the 'substituted judgment' standard—deciding what the patient would have chosen) and the Living Will; POLST/MOLST forms translate patient values into actionable, legally binding medical orders that travel across all healthcare settings.

Palliative care is appropriate at ANY stage of serious illness alongside curative and life-prolonging treatments; Hospice care is specialized end-of-life comfort care indicated when estimated life expectancy is ≤6 months if the disease follows its natural course, requiring the patient to forego curative intent.

Equianalgesic opioid ratios: Oral Morphine 30 mg = Oral Oxycodone 20 mg = Oral Hydromorphone 7.5 mg = IV Morphine 10 mg = IV Hydromorphone 1.5 mg; in advanced chronic kidney disease or renal failure, fentanyl and methadone are the safest opioids because morphine and oxycodone form active neurotoxic glucuronide metabolites (M3G/M6G) that accumulate, causing myoclonus, hyperalgesia, and seizures.

Opioid-induced constipation occurs in virtually 100% of patients; tolerance NEVER develops to constipation, necessitating mandatory co-prescribing of a stimulant laxative (senna 1–2 tablets daily) ± osmotic agent (polyethylene glycol 3350); docusate monotherapy is ineffective.

Refractory dyspnea at the end of life is treated first-line with low-dose systemic opioids (oral morphine 5–10 mg q3–4h PRN) and a bedside fan blowing cool air across the face (trigeminal V2/V3 mechanoreceptor stimulation); supplemental oxygen provides no benefit over medical air in non-hypoxemic dyspnea; terminal secretions ('death rattle') are managed with repositioning and glycopyrrolate (which does not cross the blood-brain barrier, avoiding central delirium).

Last updated: October 2026

Advance Care Planning (ACP) & Legal Instruments

Advance care planning is a proactive, iterative communication process wherein patients identify their values, define personal goals for future medical care, and designate trusted surrogate decision-makers. Effective ACP conducted in primary care reduces unwanted invasive interventions, decreases family bereavement trauma, and improves concordance between patient wishes and end-of-life care.

The Core Legal & Clinical Documents ADVANCE CARE PLANNING INSTRUMENTS IN CLINICAL PRACTICE

Document / Order Key Characteristics & Legal Authority Clinical Application & Setting

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Durable Power of • Appoints a legal Healthcare Proxy / Surrogate • Operates ONLY when the patient

Attorney for Healthcare • Empowered to make medical decisions if and when lacks decision-making capacity.

(DPOA-HC / Healthcare Proxy) the patient loses decision-making capacity. • Applies across all care settings.

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• Living Will • Instructional directive specifying treatments • Activated only in terminal illness,
• desired or refused (e.g., mechanical ventilation, end-stage condition, or persistent

CPR, hemodialysis, artificial nutrition/hydration). vegetative state with lost capacity.

• ───────────────────────────────────────────────────────────────────────────────────────────────────────────
• POLST / MOLST • ACTIONABLE, SIGNED MEDICAL ORDERS • Designed for seriously ill or frail

(Physician / Medical Orders (Translates patient goals into immediate medical patients with limited life expectancy.

for Life-Sustaining Treatment) orders: CPR status, intubation, feeding tubes). • Legally binding on EMS, ERs, nursing

• Signed by licensed clinician AND patient/proxy. homes, and acute care hospitals.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Ethical Standards for Surrogate Decision-Making

When a patient loses medical decision-making capacity, the surrogate decision-maker must adhere to a strict ethical hierarchy:

Substituted Judgment Standard (Primary Standard) : The surrogate must decide based on what the patient WOULD HAVE chosen if they were still able to speak for themselves, reconstructing the patient's explicit statements, personal philosophy, religious beliefs, and previous values.

Best Interests Standard (Secondary Standard) : Used ONLY when the patient's personal wishes are unknown or cannot be ascertained (e.g., an individual who has been cognitively impaired since childhood). The surrogate and medical team decide what a reasonable person would choose to maximize net benefit and minimize pain and suffering.

Palliative Care vs. Hospice Care

Distinguishing palliative care from hospice is an essential competency for board certification:

Palliative Care : Specialized medical care for people living with a serious, life-limiting illness. Focused on providing relief from the symptoms, pain, and physical/psychological stress of the condition.

Timing : Appropriate at ANY age and at ANY stage of a serious illness.

Concurrent Care : Delivered SIMULTANEOUSLY with curative, life-prolonging, disease-modifying therapies (e.g., palliative care concurrent with adjuvant chemotherapy, radiation, hemodialysis, or heart failure GDMT).

Hospice Care : A specialized model and Medicare/insurance benefit of comprehensive comfort-focused care delivered at the end of life.

Eligibility Criterion : Two physicians (the hospice medical director and attending physician) must certify that the patient has a terminal illness with a life expectancy of ≤ 6 \le 6 ≤ 6 months if the disease follows its natural course.

Treatment Intent : The patient and family elect to forego curative, disease-directed, or life-prolonging interventions in favor of comfort, symptom management, and dignity.

Interdisciplinary Coverage : Encompasses medical care, nursing, 24/7 on-call coverage, pharmaceuticals for symptom control, medical equipment (hospital bed, oxygen), social work, chaplaincy, and bereavement support for up to 1 year after the death for surviving family members.

End-of-Life Symptom Management: Pain

Pain occurs in over 70–80% of patients with advanced cancer and non-cancer terminal illnesses. The WHO analgesic ladder provides a framework: mild pain (acetaminophen, NSAIDs), mild-to-moderate pain (weak opioids), and moderate-to-severe pain (potent full opioid agonists).

Equianalgesic Dosing & Opioid Conversions

When rotating opioids due to refractory pain, adverse effects, or transitioning between oral and intravenous routes, precise equianalgesic calculations are required: OPIOID EQUIANALGESIC CONVERSION MATRIX

• Opioid Drug Oral Dosing (mg) Parenteral (IV/SC) Dosing (mg)
• ════════════════════════════════════════════════════════════════════════════════════════════
• Morphine 30 mg 10 mg (1:3 IV-to-Oral Ratio)
• ────────────────────────────────────────────────────────────────────────────────────────────
• Oxycodone 20 mg -- (No IV in US)
• ────────────────────────────────────────────────────────────────────────────────────────────
• Hydromorphone (Dilaudid) 7.5 mg 1.5 mg (1:5 IV-to-Oral Ratio)
• ────────────────────────────────────────────────────────────────────────────────────────────
• Fentanyl -- 100 mcg (0.1 mg) IV
• (Transdermal Patch) (25 mcg/hr transdermal patch ≈ 60–90 mg oral morphine equivalents/day)
• ────────────────────────────────────────────────────────────────────────────────────────────
• Methadone Variable (Non-linear conversion due to long t1/2 and NMDA activity)
• ════════════════════════════════════════════════════════════════════════════════════════════

Incomplete Cross-Tolerance Rule : When rotating from one opioid to another due to intolerable side effects or uncontrolled pain, calculate the equianalgesic dose and REDUCE by 25% to 50% to account for incomplete cross-tolerance across opioid receptor subtypes.

Breakthrough Pain Prescription : For patients on round-the-clock baseline opioids, prescribe an immediate-release short-acting opioid for breakthrough pain:

Dose: 10% to 15% of the total 24-hour baseline oral morphine equivalent (OME) requirement .

Frequency: Prescribed every 1 to 2 hours PRN orally , or every 15 to 30 minutes IV.

Renal Impairment & Opioid Neurotoxicity

Renal failure fundamentally dictates safe opioid selection in palliative care:

Morphine : Metabolized by the liver into Morphine-6-glucuronide (M6G) (potent analgesic and respiratory depressant) and Morphine-3-glucuronide (M3G) (non-analgesic, neurotoxic). Both metabolites are eliminated 100% by the kidneys . In renal failure (eGFR < 30 mL/min <30\text{ mL/min} < 30 mL/min ), M3G and M6G accumulate massively, triggering severe opioid neurotoxicity : multifocal myoclonus, tactile allodynia, hyperalgesia, delirium, seizures, and respiratory arrest.

Oxycodone & Hydromorphone : Hydromorphone is metabolized to hydromorphone-3-glucuronide (H3G; neurotoxic). It can be used with extreme caution and reduced doses in mild-to-moderate renal disease, but accumulates in severe CKD.

SAFEST OPIOIDS IN ADVANCED RENAL FAILURE / DIALYSIS :

Fentanyl : Metabolized entirely by hepatic CYP3A4 to inactive metabolites (norfentanyl) with zero active renal metabolites. It is the preferred opioid in acute renal failure or dialysis .

Methadone : Hepatically metabolized and eliminated primarily via feces/biliary system; no active renal metabolites. Safe in renal failure, but requires expert monitoring due to variable half-life (15–120 hours) and QTc prolongation.

The Cardinal Rule: Opioid-Induced Bowel Dysfunction

[!CRITICAL] Opioid-Induced Constipation (OIC) Prophylaxis Opioids bind peripheral mu-opioid receptors in the myenteric and submucosal plexuses of the gastrointestinal tract, causing tonic circular muscle contraction, halting propulsive peristalsis, and increasing fluid absorption from stool.

Tolerance to constipation NEVER develops (unlike tolerance to nausea, sedation, or pruritus, which resolves within 3–7 days).

MANDATORY CO-PRESCRIPTION : Every patient started on round-the-clock opioids MUST SIMULTANEOUSLY BE PRESCRIBED A PROPHYLACTIC BOWEL REGIMEN .

First-Line Regimen : A stimulant laxative (Senna 1–2 tablets PO daily or bisacodyl 10 mg PO daily) combined with an osmotic laxative (Polyethylene Glycol [PEG 3350] 17 g daily).

Clinical Trap : Docusate sodium stool softener monotherapy is completely INEFFECTIVE in randomized clinical trials; it acts as a weak detergent and does not stimulate the propulsive peristalsis halted by opioids.

Refractory OIC : Peripherally acting mu-opioid receptor antagonists (PAMORAs; e.g., methylnaltrexone 12 mg subcutaneous injection). Methylnaltrexone does not cross the blood-brain barrier, immediately inducing bowel evacuation within 30–60 minutes without reversing central analgesia or precipitating opioid withdrawal.

• End-of-Life Symptom Management: Dyspnea, Secretions & Delirium
• 1. Refractory Dyspnea (Air Hunger)

Dyspnea is among the most terrifying symptoms experienced by patients with end-stage COPD, heart failure, ALS, and lung cancer. Dyspnea represents a mismatch between central motor respiratory drive and afferent mechanical feedback from chest wall mechanoreceptors.

Systemic Opioids — First-Line Pharmacotherapy :

Mechanism : Low-dose opioids (e.g., oral morphine 5 to 10 mg PO every 3–4 hours PRN , or 2.5–5 mg IV) blunt central medullary sensitivity to hypercapnia and hypoxia, decrease central perception of breathlessness, and alleviate secondary anxiety.

Clinical Safety : Extensive clinical trials demonstrate that carefully titrated low-dose opioids relieve dyspnea WITHOUT causing respiratory depression or shortening survival in terminally ill patients.

Bedside Fan Therapy (Non-Pharmacological First-Line) :

Directing a portable electric fan blowing cool air across the patient's cheek, nose, and mouth stimulates mechanoreceptors in the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve .

This sends inhibitory afferents to the brainstem respiratory center, significantly decreasing the sensation of air hunger. It is as effective as supplemental oxygen in non-hypoxemic patients.

Supplemental Oxygen Restrictions :

Indicated ONLY if objective hypoxemia is documented ( S a O 2 < 88 − 90 % S_aO_2 < 88-90\% S a ​ O 2 ​ < 88 − 90% ) .

In non-hypoxemic patients, high-flow supplemental oxygen provides zero symptom relief compared to room air and causes nasal mucosal crusting, drying, and epistaxis.

2. Terminal Secretions ("The Death Rattle")

In the final 24 to 48 hours of life, severely somnolent, comatose, or dying patients lose their swallowing and cough reflexes. Saliva, mucus, and bronchial secretions pool in the hypopharynx and upper airways, creating oscillating, coarse, noisy respirations during inspiration and expiration.

Communication Pearl : Terminal secretions rarely cause distress to the unconscious patient, but cause intense emotional anguish to bedside family members who mistake it for choking or suffocating. Education and reassurance are paramount.

First-Line Non-Pharmacologic Action : Reposition the patient into a lateral side-lying or semi-prone position , elevating the head of the bed to promote passive postural gravitational drainage. Perform gentle oral hygiene with moist foam swabs.

AVOID AGGRESSIVE TRACHEOPHARYNGEAL SUCTIONING : Deep suctioning induces gagging, coughing, bronchospasm, mucosal hemorrhage, and agitation without clearing hypopharyngeal pooling.

Anticholinergic / Antimuscarinic Pharmacotherapy :

Glycopyrrolate (Robinul) : 0.2 to 0.4 mg SC or IV every 4 hours PRN (or continuous infusion). PREFERRED AGENT because it is a quaternary ammonium compound with high water solubility that DOES NOT CROSS THE BLOOD-BRAIN BARRIER . It treats secretions without causing central anticholinergic delirium or sedation.

Scopolamine : Transdermal patch (1.5 mg replaced every 72 hours) or subcutaneous injection (0.4 mg q4h). Crosses the blood-brain barrier; provides sedation but carries a significant risk of worsening central delirium.

Hyoscyamine : 0.125 to 0.25 mg sublingually or orally every 4 hours.

3. Terminal Delirium & Agitation

Hyperactive delirium (restlessness, purposeless plucking at sheets, hallucinations, vocalizations) develops in over 80% of dying individuals in their final days.

Reversible Etiology Assessment : Rapidly assess for easily remediable triggers: acute urinary retention (place urinary catheter), severe fecal impaction, unmanaged pain, or medication toxicity.

Pharmacologic Management :

Haloperidol (First-Line) : 0.5 to 2.0 mg PO, SC, or IV every 2 to 4 hours PRN. A high-potency dopamine antagonist with minimal sedating or anticholinergic effects.

Atypical Antipsychotics : Olanzapine (2.5–5 mg PO/ODT) or Quetiapine (25–50 mg PO) for mild agitation with intact swallowing.

Refractory Agitation & Palliative Sedation :

When delirium or distress is intractable and refractory to all targeted medical interventions, palliative sedation may be initiated following multidisciplinary palliative consultation and informed family consent.

Midazolam continuous subcutaneous or IV infusion (titrated from 0.5–2 mg/hr) or propofol is administered to relieve intractable suffering, without the intent to hasten death.

Loading diagram... Comprehensive End-of-Life Symptom Management: Palliative Care Pathways